Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes

Neurology. 2009 Mar 17;72(11):1008-15. doi: 10.1212/01.wnl.0000344417.42972.54.

Abstract

In this essay, we draw attention to some recent downsides and surprises of multiple sclerosis (MS) therapeutics. These include experiences with recent head-to-head trials of interferon-beta and glatiramer acetate, dose escalation trials, frustrating efforts with progressive MS trials, failures of smart concepts and designer therapies, and harsh lessons from newly observed adverse reactions.

Publication types

  • Review

MeSH terms

  • Child
  • Disease Progression
  • Dose-Response Relationship, Drug
  • Drug Design
  • Glatiramer Acetate
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Interferon Type I / adverse effects
  • Interferon Type I / therapeutic use*
  • Multiple Sclerosis / complications
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / pathology
  • Multiple Sclerosis / therapy*
  • Peptides / adverse effects
  • Peptides / therapeutic use*
  • Recombinant Proteins
  • Research Design
  • Treatment Failure
  • Treatment Outcome

Substances

  • Immunosuppressive Agents
  • Interferon Type I
  • Peptides
  • Recombinant Proteins
  • Glatiramer Acetate